m6A-centered Disease Response Information

General Information of the Disease (ID: M6ADIS0177)
Name
Diffuse large B-cell lymphomas
ICD
ICD-11: 2A81
Full List of Target Gene(s) of This m6A-centered Disease Response
Pigment epithelium-derived factor (PEDF)
 Target Info 
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene [3]
Response Summary Overexpressed Pigment epithelium-derived factor (PEDF) abrogates the inhibition of cell proliferation in DLBCL cells that is caused by METTL3 silence.
Responsed Disease Diffuse large B-cell lymphomas [ICD-11: 2A81]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
In-vitro Model U-2932 Diffuse large B-cell lymphoma Homo sapiens CVCL_1896
SU-DHL-4 Diffuse large B-cell lymphoma Homo sapiens CVCL_0539
OCI-Ly10 Diffuse large B-cell lymphoma Homo sapiens CVCL_8795
HBL-1 [Human diffuse large B-cell lymphoma] Diffuse large B-cell lymphoma Homo sapiens CVCL_4213
GM12878 Human B lymphocytes Homo sapiens CVCL_7526
Farage Diffuse large B-cell lymphoma Homo sapiens CVCL_3302
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Disease
In total 2 item(s) under this disease
Crosstalk ID: M6ACROT05328
 Crosstalk Info 
m6A Regulator Wilms tumor 1-associating protein (WTAP)
 Regulator Info 
m6A Target Hexokinase-2 (HK2)
 Target Gene 
Epigenetic Regulator piR-30473
Regulated Target Pre-mRNA-splicing regulator WTAP (WTAP)
Crosstalk relationship ncRNA → m6A
Crosstalk ID: M6ACROT05836
 Crosstalk Info 
m6A Regulator Methyltransferase-like 14 (METTL14)
 Regulator Info 
m6A Target X inactive specific transcript (XIST)
 Target Gene 
Epigenetic Regulator X inactive specific transcript (XIST)
Crosstalk relationship m6A → ncRNA
References
Ref 1 US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression.
Ref 2 Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. Br J Pharmacol. 2011 Feb;162(4):989-99. doi: 10.1111/j.1476-5381.2010.01104.x.
Ref 3 The m6A Methyltransferase METTL3 Is Functionally Implicated in DLBCL Development by Regulating m6A Modification in PEDF. Front Genet. 2020 Aug 27;11:955. doi: 10.3389/fgene.2020.00955. eCollection 2020.
Ref 4 Magnitude of Therapeutic STING Activation Determines CD8(+) T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018 Dec 11;25(11):3074-3085.e5. doi: 10.1016/j.celrep.2018.11.047.
Ref 5 FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
Ref 6 Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81. doi: 10.1016/j.clpt.2006.09.003.